Premium
New insights into Brunner syndrome and potential for targeted therapy
Author(s) -
Palmer E.E.,
Leffler M.,
Rogers C.,
Shaw M.,
Carroll R.,
Earl J.,
Cheung N.W.,
Champion B.,
Hu H.,
Haas S.A.,
Kalscheuer V.M.,
Gecz J.,
Field M.
Publication year - 2016
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1111/cge.12589
Subject(s) - serotonergic , serotonin , monoamine oxidase , aggression , psychology , serotonin reuptake inhibitor , medicine , serotonin syndrome , psychiatry , endocrinology , biology , biochemistry , receptor , enzyme
We report two families with Brunner syndrome living in one state of Australia. The first family had a predicted protein‐truncating variant of monoamine oxidase A ( MAOA ) ( p.S251KfsX2 ). Affected males had mild intellectual disability ( ID ), obsessive behaviour, limited friendships and were introverted and placid during clinical interview. The family disclosed episodic explosive aggression after a diagnosis was made. The second family had a missense variant in MAOA ( p.R45W ). Affected males had borderline‐mild ID , attention deficit disorder and limited friendships. One had a history of explosive aggression in childhood and episodic symptoms of flushing, headaches and diarrhoea. Their carrier mother had normal intelligence but similar episodic symptoms. Characteristic biochemical abnormalities included high serum serotonin and urinary metanephrines and low urinary 5‐hydroxyindoleacetic acid (5‐ HIAA ) and vanillylmandelic acid ( VMA ). Symptomatic individuals in the second family had particularly high serotonin levels, and treatment with a serotonin reuptake inhibitor and dietary modification resulted in reversal of biochemical abnormalities, reduction of ‘serotonergic’ symptoms and behavioural improvement. Brunner syndrome should be considered as a cause of mild ID with paroxysmal behavioural symptoms. It can be screened for with serum/urine metanephrine and serotonin measurement. Cautious treatment with a serotonin reuptake inhibitor, dietary modifications and avoidance of medications contraindicated in patients on monoamine oxidase inhibitors can improve symptoms.